DAXXIFY Becomes First Facial Injectable to be Named to TIME’s Best Inventions - Seite 2

The efficacy and safety profile of DAXXIFY is backed by more than 20 years of research and development and the largest U.S. Phase 3 clinical program ever conducted for glabellar lines. DAXXIFY’s differentiated performance profile is achieved through its unique formulation, powered by Revance’s proprietary Peptide Exchange Technology, a stabilizing peptide excipient which does not require human or animal-based components. Further, in a recent independent survey, DAXXIFY injectors revealed that the product has additional benefits extending beyond duration, including fast onset of treatment effect and the appearance of improved skin smoothness.³

“The launch of DAXXIFY piqued my interest on many levels, especially compared to recent conventional neuromodulator launches,” said Ruth Tedaldi, M.D., founder of Dermatology Partners. “Over the last year it's been a definite game changer in my practice as DAXXIFY provides me with the ability to bring to my patients what they're asking for – long-lasting results and improved appearance of skin texture.”

Jody Comstock, M.D., founder of Skin Spectrum, commented, “DAXXIFY’s unique formulation sets it apart from all conventional neuromodulators on the market today. As the only neuromodulator that is stabilized with a peptide rather than human or animal-based components, I’ve been able to provide my patients with the first truly differentiated treatment option. The innovation behind DAXXIFY combined with the fast onset and long-lasting results has made it the go-to neuromodulator in my practice.”

DAXXIFY’s label recently expanded in August 2023 to include the treatment of cervical dystonia, a chronic, debilitating disease in which the neck muscles contract involuntarily, and has the potential to deliver significant pharmacoeconomic benefits through its long-lasting treatment of effect.

* 62% of patients achieved an improvement in skin texture at week 2 in a phase 2 study

DAXXIFY (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION INDICATIONS

DAXXIFY (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

The effects of DAXXIFY and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.